Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
New study looks at long-term impacts in people with prostate, bladder, colorectal and lung cancers
Tumors with large numbers of genetic mutations may be especially susceptible to treatment with immunotherapy.
The 30% improvement in survival has brought a Phase III trial to an early halt.
The antibody-drug conjugate nearly doubled survival time for people with triple-negative breast cancer.
The immunotherapy is now approved for people whose cancer has not progressed on platinum-based chemotherapy.
“Potentially practice-changing” data show patients with advanced urothelial carcinoma survive longer with immune-boosting drug after chemo.
More than half of patients treated with mitomycin experienced complete tumor remission.
Last year, the FDA approved three new antibody-drug conjugates for treating cancer.
Genitourinary Cancers Symposium reaches beyond the latest prostate, bladder and kidney cancer treatments.
Updated study results show antibody-drug conjugate plus Keytruda shrinks tumors in 73% of patients.
In a clinical trial, 46% of responding participants experienced a complete response lasting at least 12 months.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.